{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T04:27:21Z","timestamp":1792297641065,"version":"4.4.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ucl.2025.07.006","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T23:09:51Z","timestamp":1756422591000},"page":"605-615","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Review of Current Guidelines and Innovations in Benign Prostatic Hyperplasia Evaluation and Management"],"prefix":"10.1016","volume":"52","author":[{"given":"Jaspreet S.","family":"Sandhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1549","key":"10.1016\/j.ucl.2025.07.006_bib1","article-title":"The american urological association symptom index for benign prostatic hyperplasia. The measurement committee of the american urological association","volume":"148","author":"Barry","year":"1992","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2025.07.006_bib2","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/JU.0000000000002183","article-title":"Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I, initial work-up and medical management","volume":"206","author":"Lerner","year":"2021","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2025.07.006_bib3","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/JU.0000000000002184","article-title":"Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART II\u2014surgical evaluation and treatment","volume":"206","author":"Lerner","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.07.006_bib4","article-title":"Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA Guideline amendment 2023","volume":"10","author":"Sandhu","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.07.006_bib5","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1345\/aph.18263","article-title":"Tamsulosin for the treatment of benign prostatic hypertrophy","volume":"34","author":"Lee","year":"2000","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.ucl.2025.07.006_bib6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1046\/j.1464-410X.2003.04309.x","article-title":"Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies","volume":"92","author":"Roehrborn","year":"2003","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.ucl.2025.07.006_bib7","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1016\/j.juro.2009.02.034","article-title":"Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies","volume":"181","author":"Leonard","year":"2009","journal-title":"J Urol"},{"issue":"40","key":"10.1016\/j.ucl.2025.07.006_bib8","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ophtha.2018.11.028","article-title":"Evolution in the risk of cataract surgical complications among patients exposed to tamsulosin: a population-based study","volume":"126","author":"Campbell","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ucl.2025.07.006_bib9","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s11934-004-0050-6","article-title":"The role of 5-\u03b1-reductase inhibition as monotherapy in view of the MTOPS data","author":"Sandhu","year":"2004","journal-title":"Curr Urol Rep"},{"issue":"6 Suppl 1","key":"10.1016\/j.ucl.2025.07.006_bib10","first-page":"65","article-title":"5alpha-reductase inhibitors: what role should they play?","volume":"58","author":"Kalpan","year":"2001","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.ucl.2025.07.006_bib11","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.juro.2013.12.014","article-title":"Change in sexual function in men with lower urinary tract symptoms\/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy","volume":"191","author":"Fwu","year":"2014","journal-title":"J Urol"},{"issue":"11","key":"10.1016\/j.ucl.2025.07.006_bib12","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1111\/j.1743-6109.2012.02846.x","article-title":"Persistent sexual side effects of finasteride: could they be permanent?","volume":"9","author":"Irwig","year":"2012","journal-title":"J Sex Med"},{"issue":"3","key":"10.1016\/j.ucl.2025.07.006_bib13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","article-title":"Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study","volume":"175","author":"Gray","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ucl.2025.07.006_bib14","doi-asserted-by":"crossref","unstructured":"Kevin T McVary. J Urol. Apr 2007;177(4):1401-1407.","DOI":"10.1016\/j.juro.2006.11.037"},{"issue":"1 suppl","key":"10.1016\/j.ucl.2025.07.006_bib15","first-page":"S135","article-title":"Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial","volume":"189","author":"Dmochowski","year":"2013","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2025.07.006_bib16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.juro.2017.01.075","article-title":"AUA white paper on nonneurogenic chronic urinary retention: consensus definition, treatment algorithm, and outcome end points","volume":"198","author":"Stoffel","year":"2017","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2025.07.006_bib17","first-page":"8802","article-title":"Five year results of the prospective randomized controlled prostatic urethral l.I.F.T. Study","volume":"24","author":"Roehrborn","year":"2017","journal-title":"Can J Urol"},{"issue":"5","key":"10.1016\/j.ucl.2025.07.006_bib18","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.juro.2015.10.181","article-title":"Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"195","author":"McVary","year":"2016","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2025.07.006_bib19","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/JU.0000000000001778","article-title":"Final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor thermal therapy for treatment of moderate to severe lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"206","author":"McVary","year":"2021","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.ucl.2025.07.006_bib20","first-page":"10824","article-title":"Prostatic urethral lift (UroLift) versus convective water vapor ablation (Rezum) for minimally invasive treatment of BPH: a comparison of improvements and durability in 3-year clinical outcomes","volume":"28","author":"Elterman","year":"2021","journal-title":"Can J Urol"},{"key":"10.1016\/j.ucl.2025.07.006_bib21","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.urology.2020.12.022","article-title":"The iTind temporarily implanted nitinol device for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a multicenter, randomized, controlled trial","volume":"153","author":"Bilal","year":"2021","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.ucl.2025.07.006_bib22","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.eururo.2019.11.010","article-title":"Randomised clinical trial of prostatic artery embolisation versus a sham procedure for benign prostatic hyperplasia","volume":"77","author":"Pisco","year":"2020","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2025.07.006_bib23","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1148\/radiol.13122803","article-title":"Benign prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostate--a prospective, randomized, and controlled clinical trial","volume":"270","author":"Gao","year":"2014","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.ucl.2025.07.006_bib24","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1464-410X.2011.10359.x","article-title":"Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the prostate: results at 7 years","volume":"109","author":"Gilling","year":"2012","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.ucl.2025.07.006_bib25","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.eururo.2013.10.040","article-title":"180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European Multicentre Randomised Trial--the GOLIATH study","volume":"65","author":"Bachmann","year":"2014","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2025.07.006_bib26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.eururo.2015.07.054","article-title":"A multicenter randomized noninferiority trial comparing GreenLight-XPS laser vaporization of the prostate and transurethral resection of the prostate for the treatment of benign prostatic obstruction: two-yr outcomes of the GOLIATH study","volume":"69","author":"Thomas","year":"2016","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ucl.2025.07.006_bib27","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/bju.15161","article-title":"Randomised trial of bipolar resection vs holmium laser enucleation vs Greenlight laser vapo-enucleation of the prostate for treatment of large benign prostate obstruction: 3-years outcomes","volume":"126","author":"Elshal","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2025.07.006_bib28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.urology.2018.12.002","article-title":"Randomized controlled trial of aquablation versus transurethral resection of the prostate in benign prostatic hyperplasia: one-year outcomes","volume":"125","author":"Gilling","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2025.07.006_bib29","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.urology.2022.04.004","article-title":"WATER vs WATER II 3-year update: comparing aquablation therapy for benign prostatic hyperplasia in 30-80 cc and 80-150 cc prostates","volume":"165","author":"Assad","year":"2022","journal-title":"Urology"},{"issue":"11","key":"10.1016\/j.ucl.2025.07.006_bib30","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1089\/end.2017.0489","article-title":"Robot-assisted versus open simple prostatectomy for benign prostatic hyperplasia in large glands: a propensity score-matched comparison of perioperative and short-term outcomes","volume":"31","author":"Sorokin","year":"2017","journal-title":"J Endourol"},{"issue":"S1","key":"10.1016\/j.ucl.2025.07.006_bib31","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1089\/end.2017.0715","article-title":"Robot-assisted simple prostatectomy","volume":"32","author":"Cockrell","year":"2018","journal-title":"J Endourol"},{"issue":"2","key":"10.1016\/j.ucl.2025.07.006_bib32","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11701-021-01236-1","article-title":"Single-port robotic-assisted simple prostatectomy is associated with decreased post-operative narcotic use in a propensity score matched analysis","volume":"16","author":"Ganesan","year":"2022","journal-title":"J Robot Surg"},{"issue":"8","key":"10.1016\/j.ucl.2025.07.006_bib33","doi-asserted-by":"crossref","DOI":"10.1007\/s11934-019-0907-3","article-title":"Cost comparison of benign prostatic hyperplasia treatment options","volume":"20","author":"DeWitt-Foy","year":"2019","journal-title":"Curr Urol Rep"},{"issue":"3","key":"10.1016\/j.ucl.2025.07.006_bib34","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.eururo.2012.10.005","article-title":"A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia","volume":"63","author":"Marberger","year":"2013","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2025.07.006_bib35","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00345-018-2185-y","article-title":"Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement","volume":"36","author":"Shore","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.ucl.2025.07.006_bib36","first-page":"31","article-title":"Intrinsic and extrinsic factors controlling benign prostatic growth","author":"Lee","year":"1997","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.ucl.2025.07.006_bib37","first-page":"154","article-title":"Role of prostate stem cells and treatment strategies in benign prostate hyperplasia","volume":"10","author":"Gangavarapu","year":"2022","journal-title":"Am J Clin Exp Urol"},{"issue":"2","key":"10.1016\/j.ucl.2025.07.006_bib38","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1517\/13543780903555196","article-title":"NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia","volume":"19","author":"Shore","year":"2010","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014325000618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014325000618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T22:25:31Z","timestamp":1760567131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014325000618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0094014325000618"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2025.07.006","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Review of Current Guidelines and Innovations in Benign Prostatic Hyperplasia Evaluation and Management","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2025.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}